Leukotriene-D4 induced cell shrinkage in Ehrlich ascites tumor cells.
The nature of the leukotriene-D4 (LTD4) induced cell shrinkage in Ehrlich ascites tumor cells has been investigated. LTD4 treatment of Ehrlich cells induces net loss of cellular KCl and cell shrinkage independent of the initial cell volume. LTD4 also produces water loss and reduction in cell volume when all extracellular and all intracellular Cl has been replaced by NO3. On the other hand, LTD4 fails to produce any significant changes in cell volume in the presence of the K-channel blocker quinine, suggesting that LTD4 in Ehrlich cells induces Cl-independent K loss through the Ca2+-dependent K channels. However, the effect of physiological doses of LTD4 on cell volume seems not to be as potent in Cl-free, NO3 cells when compared to Cl-containing cells, indicating that LTD4 in Ehrlich cells also provokes Cl-dependent K loss. LTD4 seems not to produce K loss through an electroneutral K+/H+ exchange system. LTD4 still produces Cl-independent K loss and cell shrinkage in the presence of the anti-calmodulin drug pimozide but not in the presence of the LTD4 receptor antagonist L-649,923 or the 5-lipoxygenase inhibitor NDGA. Pretreatment of the cells with pertussis toxin, which inactivates inhibitory guanine nucleotide binding proteins (G-proteins), leads to partial inhibition of the LTD4-induced shrinkage. It is suggested that the LTD4-induced activation of K and Cl transporting systems in Ehrlich ascites tumor cells is mediated via a G-protein coupled receptor and that LTD4 might exert its effect through another lipoxygenase product. The Ca2+-calmodulin complex is not involved in the LTD4-induced activation of K and Cl transporting systems.
Lambert
I H
IH
Institute of Biological Chemistry, August Krogh Institute, University of Copenhagen, Denmark.
D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002147:Calmodulin / Q000378:metabolism; D002286:Carcinoma, Ehrlich Tumor / Q000473:pathology*; D002712:Chlorides / Q000493:pharmacokinetics; D019204:GTP-Binding Proteins / Q000378:metabolism; D007473:Ion Channels / Q000187:drug effects / Q000502:physiology; D008084:Lipoxygenase / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D010868:Pimozide / Q000494:pharmacology; D011188:Potassium / Q000493:pharmacokinetics; D011803:Quinine / Q000494:pharmacology; D011971:Receptors, Immunologic / Q000378:metabolism; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014882:Water-Electrolyte Balance / Q000187:drug effects
D002147:Calmodulin; D002712:Chlorides; D007473:Ion Channels; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; D010868:Pimozide; D011803:Quinine; D008084:Lipoxygenase; D019204:GTP-Binding Proteins; D011188:Potassium; D002118:Calcium